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Introduction
Methods
We first synthetized the labeling precursor 1 (Figure 2) as previously reported in
literature.[3] The three-step synthetic pathway synthesis was implemented on a
GE Healthcare FastLabTM.
Conclusions
We successfully radiolabeled a Cys-tagged Nanofitin with [18F]-FBEM automated synthetized at high activity. A simple and new method for the radiolabeling of
biomolecule with high yield (up to 61%) on Ni magnetic beads was developed. PET-MRI studies on mice were conduct after injection of [18F]-NF in order to know
the biodistribution of this Nanofitin model. The results show a fast renal clearance and an uptake in the liver. The metabolites are excreted by kidneys through
urine and by the liver via biliary excretion to the intestine.
References
The formation of a C-18F bond requiring hard conditions, an alternative method developed few decades ago consists
in incorporating the 18F on a prosthetic group and then coupling it to the biomolecule by bioorthogonal reactions.[1-2]
Following a similar strategy, a single cysteine has been incorporated in a Nanotifin(NF) model and its regioselective
radiolabeling has been performed with [18F]-4-fluorobenzamido-N-ethylamino-maleimide ([18F]-FBEM).
Coupling with the [18F]-FBEM has been achieved on Ni magnetic beads system. PET-MRI studies on mice were
conduct after injection of [18F]-FBEM-Cys-NF in order to know the biodistribution of this NF model.
Figure 2 Radiosynthesis of [18F]-FBEM
The labeling was then done on a selected model histagged NF that has been
reengineered to bear a unique cysteine. This cysteine leads to the dimerization of
the NF via a disulfide bridge which needs to be reduced before the coupling. To
overcome the reduction of the maleimide moiety of the [18F]-FBEM in presence of
reducing agent, the NF was first trapped on Ni-NTA magnetic beads and then
reduction and labeling were proceeded successively on-bead (Figure 4).
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Figure 4 Radiolabeling of Nanofitin with [18F]-FBEM on Ni-NTA magnetic beads
Figure 1 Scheme of radiosynthesis of [18F]-FBEM-Cys-NF
Results
Radiochemical yield(RCY) of [18F]-FBEM synthesis was 28.7±3.2% (n=10) and
lasted 90 min including purification.
The RCY obtained for NF labeling is 53.8±7.3% (n=9) with a radiochemical
purity >95%.
Figure 5 Analytical C8-HPLC of the [18F]-NF
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Figure 7 Evolution of the %ID/g for the kidneys and the liver
Nanofitins
• Small protein (+/-10kDa)
• pH stability (0-13)
• Temperature stability (Tm ≈ 80°C)
• Produced by Sac7D bacteria
• Alternative to antibodies
• Cysteine-free protein
Figure 3 Cassette layout for [18F]-FBEM preparation
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